EMCURE - IntraDay Trade Analysis with Live Signals

Last Updated Time : 05 Nov 25, 7:43 am

IntraDay Trade Rating: 3.5

📊 Strong institutional support and valuation strength offer a tactical setup, though weak momentum and volume suggest cautious execution.

📈 Positive

• 📈 DII holding increased by 1.52% — strong domestic institutional confidence.
• 📈 FII holding increased by 0.43% — foreign investor interest building.
• 📈 Trading above DMA 200 (₹1,310) — long-term trend remains intact.
• 📈 EPS of ₹21.1 — solid earnings base.
• 📈 Qtr Profit Var: 210% — strong YoY earnings growth.

⚠️ Limitation

• 📉 MACD at -9.41 — bearish divergence, momentum remains weak.
• 📉 RSI at 44.1 — neutral zone, lacks strong bullish confirmation.
• 📉 Volume below average (99.9K vs 1.54L) — muted intraday participation.
• 📉 Trading below DMA 50 (₹1,356) — short-term trend under pressure.
• 📉 PEG ratio of -4.61 — valuation misaligned with growth expectations.

📰 Company Negative News

• 📉 PAT declined from ₹140 Cr. to ₹125 Cr. — sequential earnings contraction.

🌟 Company Positive News

• 📈 Strong institutional accumulation and long-term trend support despite short-term weakness.

💊 Industry

• 🧬 Operates in pharmaceuticals — defensive sector with consistent demand and export potential.
• 📊 Industry P/E of 33.1 — EMCURE trades at a premium, reflecting growth optimism.

📌 Conclusion

• 📉 Moderate intraday setup with institutional support and long-term trend intact, but weak momentum and volume suggest tight risk control.
• 💡 Optimal buy range: ₹1,320–₹1,325. Target exit: ₹1,340–₹1,355.
• 🛑 Stop-loss: ₹1,310 to manage downside risk.
• 📤 If already holding, consider exiting near ₹1,340 if RSI crosses 47 or MACD flattens intraday.

I can also help you compare EMCURE’s setup with other pharma stocks showing stronger MACD and RSI signals for intraday trades.